Extraskeletal myxoid chondrosarcoma is an extremely rare type of cancer that grows slowly in the soft tissues of the body, most often affecting the arms, legs, or areas around major joints. Though it progresses gradually over months or even years, this disease has a tendency to return locally after treatment and can spread to distant parts of the body, requiring careful long-term medical attention and a personalized approach to care.

How Treatment Approaches Aim to Help Patients with This Rare Cancer

When someone is diagnosed with extraskeletal myxoid chondrosarcoma, often abbreviated as EMC, the main goals of treatment center on removing the tumor completely, preventing it from returning, and managing any spread of the disease if it has already occurred. Because EMC behaves differently from many other cancers—growing slowly but persistently over time—treatment plans must be carefully tailored to each person’s situation. This includes considering where the tumor is located, how large it has grown, and whether the disease has already reached other parts of the body.^[1]

The treatment approach depends heavily on the stage of the disease when it is discovered. For people whose cancer is found early and has not spread beyond its original location, the focus is on removing the tumor surgically and possibly adding radiation therapy to reduce the chance of the cancer coming back. For those whose disease has already spread to distant areas like the lungs or other organs, treatment becomes more complex and may involve systemic therapies designed to slow the cancer’s growth throughout the body.^[7]

Medical guidelines from specialized cancer organizations provide doctors with frameworks for approaching EMC treatment, though the rarity of this disease means that much of what physicians know comes from studying small groups of patients over many years. There are established, standard treatments that doctors use based on decades of experience, but there is also ongoing research into newer therapies being tested in clinical trials. These investigational approaches aim to find more effective ways to control or eliminate the disease while minimizing side effects.^[2]

Standard Treatment Methods Used by Doctors Today

The cornerstone of treating localized extraskeletal myxoid chondrosarcoma is surgery. When a tumor is discovered and has not yet spread to other parts of the body, surgeons aim to remove it completely along with a surrounding margin of healthy tissue. This margin, sometimes called a clear margin, helps ensure that no microscopic cancer cells are left behind that could lead to the tumor growing back. The surgical procedure is designed not only to remove all visible tumor tissue but also to preserve as much normal function as possible, especially when the tumor is located in the arms or legs.^[2]

For tumors in the extremities, surgeons perform what is called limb-sparing surgery. This technique allows doctors to remove the cancer while keeping the affected arm or leg intact and functional. The goal is to avoid amputation whenever possible, which was more common in earlier decades. Modern surgical techniques, combined with reconstructive procedures, allow most patients to maintain their limbs and continue to use them after recovery. In rare situations where the cancer has grown extensively or has wrapped around critical blood vessels and nerves, amputation may be necessary to completely eliminate the disease and prevent it from spreading.^[2]

Studies tracking patients over many years have shown that achieving a wide surgical margin—meaning the surgeon successfully removes the tumor with a border of healthy tissue all around it—is crucial for preventing the cancer from returning in the same location. Research analyzing patient outcomes found that people who had surgery with incomplete removal of the tumor (called an R1 or R2 resection) faced a significantly higher risk of local recurrence compared to those who had complete removal with clear margins.^[11]

Radiation therapy is another treatment that doctors sometimes use in combination with surgery. This approach uses high-energy X-rays or other forms of radiation to kill cancer cells. Radiation can be given before surgery to shrink a tumor and make it easier to remove, or after surgery to destroy any cancer cells that might remain in the area. The timing and decision to use radiation depends on several factors, including the size and location of the tumor, how close it is to important structures like nerves or blood vessels, and whether the surgeon was able to achieve clear margins during the operation.^[2]

Chemotherapy, which uses drugs to kill cancer cells throughout the body, has shown limited effectiveness for EMC based on available evidence. Traditional chemotherapy regimens that work well for other types of soft tissue sarcomas (cancers that develop in the soft tissues like muscle, fat, or connective tissue) have not demonstrated convincing benefits in patients with extraskeletal myxoid chondrosarcoma. A study that followed 87 patients over more than three decades found that 21 patients received chemotherapy at various points during their treatment, but none showed significant improvement in their tumors as measured by imaging scans or clinical symptoms.^[1]

In that research, the best response doctors observed was stable disease, meaning the cancer neither shrank nor grew significantly during treatment. The average time before the disease started progressing again while patients were on chemotherapy was just over five months. These disappointing results have led many oncologists to question whether standard chemotherapy should be used routinely for EMC, particularly for patients whose disease is not causing immediate symptoms.^[1]

Despite the generally limited response to chemotherapy, some doctors may still consider it in specific situations. These might include cases where a patient has a high risk of the cancer spreading or returning, where the tumor has already spread to other organs, or where other treatment options have been exhausted. The specific drugs used vary, but they typically include combinations of medications also used for other sarcomas, such as ifosfamide and doxorubicin.^[2]

The duration of treatment with surgery and radiation varies depending on individual circumstances. Surgery is typically a one-time event, though some patients may require additional procedures if the cancer returns or if reconstructive surgery is needed. Radiation therapy, when used, is usually given over several weeks, with treatments administered five days per week. Each radiation session lasts only a few minutes, but the full course may involve 20 to 30 treatments or more.

Side effects from surgery can include pain, infection, bleeding, and complications related to wound healing. For tumors located near joints or in areas with many nerves and blood vessels, surgery can affect movement and sensation. Physical therapy and rehabilitation are often important parts of recovery. Radiation therapy side effects depend on where the treatment is directed but commonly include skin irritation resembling a sunburn in the treated area, fatigue, and tissue changes that can affect flexibility and function over time.^[2]

Long-term follow-up after treatment is critical for EMC because this cancer has a pattern of returning many years after initial treatment. Studies have shown that 37% of patients who initially presented without distant spread experienced local recurrence at an average of 3.3 years after diagnosis, while 26% developed spread to distant sites at an average of 3.2 years. Some patients experienced recurrences more than a decade after their original diagnosis, highlighting the need for ongoing surveillance with imaging scans and clinical examinations for many years.^[1]

Investigational Therapies Being Studied in Clinical Trials

Because standard treatments have shown limitations in controlling EMC, especially when the disease has spread to other parts of the body, researchers have been exploring newer types of therapies through clinical trials. These investigational approaches aim to target the specific biological characteristics of EMC that make it different from other cancers.

One of the most promising areas of research involves antiangiogenic agents—drugs that work by cutting off the blood supply that tumors need to grow. Cancer cells require nutrients and oxygen delivered through blood vessels, and they release signals that stimulate the growth of new blood vessels in a process called angiogenesis. By blocking this process, antiangiogenic drugs can potentially starve tumors and slow their growth. Early studies have suggested that these agents may be more effective for EMC than traditional chemotherapy, though research is still ongoing to confirm these findings.^[7]

Researchers have also been investigating targeted therapies that focus on the specific genetic changes found in EMC cells. Scientists have discovered that virtually all cases of extraskeletal myxoid chondrosarcoma involve a rearrangement of a gene called NR4A3. In most cases, this gene becomes fused with another gene called EWSR1, creating an abnormal protein that drives the cancer’s growth. In other cases, NR4A3 fuses with different partner genes such as TAF15, TCF12, or TFG. Understanding these genetic fusions has opened possibilities for developing drugs that specifically interfere with the abnormal proteins they produce.^[4][7]

The NR4A3 gene normally produces a protein that acts as a nuclear receptor, meaning it binds to DNA and helps control which genes are turned on or off in cells. When NR4A3 becomes fused with genes like EWSR1, the resulting abnormal protein retains the DNA-binding portion of NR4A3 but gains a powerful activation domain from the fusion partner. This hybrid protein can then turn on genes inappropriately, leading to uncontrolled cell growth and cancer development. Scientists are working to develop drugs that could block the activity of these fusion proteins or prevent them from binding to DNA.^[4]

Clinical trials testing new therapies for EMC typically proceed through several phases. Phase I trials are the first studies in humans and focus primarily on safety—determining what dose of a drug can be given without causing unacceptable side effects. These trials usually involve small numbers of patients who have advanced cancer that has not responded to standard treatments. Phase I trials help researchers understand how the body processes the drug, what side effects occur at different doses, and what dose should be used in later studies.

Phase II trials expand the testing to larger groups of patients to assess whether the drug actually has an effect against the cancer. In these studies, researchers look at whether tumors shrink, stop growing, or slow their growth when patients receive the experimental treatment. Phase II trials also continue to monitor for side effects and help determine which patients are most likely to benefit from the therapy. For rare cancers like EMC, Phase II trials are particularly important because they provide the first real evidence of whether a new approach is worth pursuing further.

Phase III trials are large studies that compare the new treatment directly against the current standard treatment. These trials randomly assign patients to receive either the experimental therapy or the standard therapy, allowing researchers to determine definitively whether the new approach is better. However, for extremely rare cancers like EMC, conducting Phase III trials can be challenging because it requires finding enough patients to participate, which may take many years or require collaboration among cancer centers across multiple countries.

One clinical trial specifically mentioned in the medical literature tested radiation therapy with or without combination chemotherapy or an investigational drug called pazopanib in patients with newly diagnosed soft tissue sarcomas, including EMC. Pazopanib is a type of targeted therapy that blocks enzymes called tyrosine kinases, which are involved in tumor growth and the development of blood vessels that feed tumors. By inhibiting these enzymes, pazopanib can potentially slow tumor growth. This trial aimed to determine whether adding pazopanib to radiation therapy could improve outcomes compared to radiation alone or radiation plus traditional chemotherapy.^[10]

The locations where clinical trials are conducted vary widely. Some trials take place at single specialized cancer centers, while others involve multiple institutions working together as part of research networks. Trials for rare cancers like EMC often include sites in the United States, Europe, and other regions to enroll enough patients. Eligibility for clinical trials depends on many factors, including the stage of disease, previous treatments received, overall health status, and specific characteristics of the tumor.

Preliminary results from some studies testing antiangiogenic agents have shown encouraging signs, with some patients experiencing stabilization of their disease or slowing of tumor growth. These results have generated interest in further investigating this class of drugs for EMC. However, it is important to understand that research is still in early stages, and these therapies are not yet proven to be effective or approved as standard treatments.^[7]

Immunotherapy represents another area of active investigation. These treatments work by harnessing the body’s immune system to recognize and attack cancer cells. While immunotherapy has shown remarkable success in some other types of cancer, research into its potential for EMC is still in very early stages. Scientists are studying whether the specific characteristics of EMC cells might make them vulnerable to immune-based attacks.^[2]

Understanding Disease Behavior and Long-Term Outcomes

One of the defining characteristics of extraskeletal myxoid chondrosarcoma is its slow but persistent nature. Unlike some aggressive cancers that grow and spread rapidly over weeks or months, EMC typically develops over years. This indolent behavior means that patients often have prolonged survival even when the disease has spread to distant sites. Studies tracking patients over 15 years or more have documented survival rates of 82% at five years, 65% at ten years, and 58% at fifteen years from diagnosis.^[1]

However, the slow growth pattern can be deceptive. Even though patients may feel well and have few symptoms for extended periods, the cancer has a strong tendency to recur locally at the original site or to spread to distant organs, most commonly the lungs. The risk of these events remains present for many years after initial treatment. Research has shown that about 13% of patients already have distant spread at the time of first diagnosis, and additional patients develop spread during follow-up.^[1]

Recent analysis of a large database of EMC patients in Japan, which included 171 cases, confirmed that people who present with distant metastases (spread to other organs) at diagnosis have significantly shorter survival compared to those without spread. The five-year disease-specific survival—meaning survival specifically from this cancer—was about 76% for patients with metastases at presentation versus 91% for those without. This finding underscores the importance of early detection before the cancer has spread.^[11]

Several factors influence how well someone does after treatment. The location of the tumor appears to matter, with tumors in the trunk of the body associated with worse outcomes compared to those in the arms or legs. Larger tumor size at diagnosis also correlates with poorer survival. These findings help doctors identify which patients may need more aggressive treatment or closer monitoring.^[11]

Interestingly, despite the tendency for EMC to spread, some patients with lung metastases can survive for many years without requiring immediate systemic treatment. Several case reports have described patients who were found to have small metastases in their lungs and were managed with careful observation rather than chemotherapy or other systemic therapy. Follow-up imaging over several years showed that while these metastases slowly grew larger, the patients remained symptom-free and maintained good quality of life without the side effects of treatment. This observation has led some doctors to adopt a “watchful waiting” approach for selected patients with asymptomatic metastatic disease.^[13]

This management strategy is based on the recognition that the slow growth of EMC metastases means that immediate treatment may not provide benefit and could potentially harm quality of life through side effects. Instead, doctors monitor patients closely with periodic imaging scans, and treatment is initiated if symptoms develop or if the metastases show signs of more rapid growth. This approach must be individualized and requires ongoing communication between patients and their medical teams.

Most Common Treatment Methods

• Surgery
  • Wide surgical removal of the tumor with clear margins of healthy tissue surrounding it
  • Limb-sparing techniques for tumors in arms or legs to preserve function while removing cancer
  • Removal with aim to achieve complete resection, as incomplete removal increases risk of local recurrence
  • Reconstructive procedures may be needed after tumor removal
  • Amputation reserved for rare cases where limb-sparing surgery is not possible
• Radiation Therapy
  • High-energy X-rays directed at the tumor site before or after surgery
  • Pre-operative radiation aims to shrink tumors and make them easier to remove
  • Post-operative radiation attempts to kill any remaining cancer cells in the surgical area
  • Effectiveness for EMC remains uncertain compared to other sarcomas
  • Typical course involves daily treatments over several weeks
• Chemotherapy
  • Systemic drug treatment using medications like ifosfamide and doxorubicin
  • Limited effectiveness demonstrated in EMC compared to other soft tissue sarcomas
  • Most patients show stable disease at best rather than tumor shrinkage
  • May be considered for high-risk patients or those with metastatic disease
  • Decision to use must weigh potential benefits against side effects
• Targeted and Antiangiogenic Therapies
  • Drugs that block blood vessel formation to tumors (antiangiogenic agents)
  • Agents targeting specific proteins involved in tumor growth, such as pazopanib
  • Approaches designed to interfere with genetic abnormalities specific to EMC, particularly NR4A3 gene fusions
  • Currently being tested in clinical trials with preliminary promising results
  • Not yet approved as standard treatment but represent area of active research
• Immunotherapy
  • Experimental approaches attempting to activate the immune system against cancer cells
  • Very early stage of research for extraskeletal myxoid chondrosarcoma
  • Potential future option as understanding of EMC biology improves
• Active Surveillance
  • Careful monitoring approach for patients with slow-growing metastatic disease
  • Regular imaging scans and clinical examinations without immediate systemic treatment
  • Allows patients to avoid treatment side effects while disease remains asymptomatic
  • Treatment initiated if symptoms develop or disease shows rapid progression
  • Based on recognition of EMC’s indolent natural history in some patients